(June. 2022 standard)
| Classification | Project Name | Treatment for | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| IMD | BR1015 | Hypertension | |||||
| BR1017 | Hypertension | ||||||
| BR1018 | Hypertension |
Pipeline
The Research Team at Boryung aims to lead the Future of the Pharmaceutical Industry
-
Pipeline Introduction
After 12 years of research, Boryung succeeded in developing the first domestic hypertension drug, ‘Kanarb’. By independently carrying out all the necessary steps – candidate material excavation, raw material synthesis, formulation research, a non-clinical trial, and clinical trial phases one, two and three – Boryung has established our very own capability for drug development. Boryung was established based on its drug development capabilities. We are expanding our scope of research into a variety of areas to develop drugs for cancer treatment, antibiotics, NCE(New Chemical Entity) and gene therapy that focuses on cardiovascular and other major diseases, vaccines and other biopharmaceuticals. We are particularly focused on the development of the Kanarb Value-Up Pipeline. In addition, we are focusing on the research and development of new API(Active Pharmaceutical Ingredient) products aimed at the globalization of API.
Pipeline
(Ju. 2024 standard)
| sification | Project Name | Treatment for | Stage | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | |||
| NCE | BR2002 | Cancer | |||||
| BR2010 | Cancer | ||||||
| BR2011 | Cancer | ||||||
| BR2018 | Cancer | ||||||
| IMD | BR1007 | CKD | |||||
| BR3003 | Diabetes | ||||||
| BR3005 | Diabetes | ||||||
| BR3006 | Diabetes | ||||||
| BR1015 | Hypertension | ||||||
| BR1017 | Hypertension/Dyslipidemia | ||||||
| BR1018 | Hypertension/Dyslipidemia | ||||||
| BR1019 | Hypertension/Diabetes | ||||||
| BR6002 | Gastrointestinal | ||||||
| Anti-cancer Generic |
BR9008 | Cancer | |||||
| BR9011 | Cancer | ||||||
| BR9012 | Cancer | ||||||
| BR2009 | Cancer | ||||||
| BR2013 | Cancer | ||||||
| BR2015 | Cancer | ||||||
| BR2016 | Cancer | ||||||
| BR2019 | Cancer | ||||||
| BR2021 | Cancer | ||||||
| BR2022 | Cancer | ||||||
Pipeline
(June. 2022 standard)
| NCE | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
BR2002 Cancer
|
||||||||||
|
BR2010 Cancer
|
||||||||||
|
BR2011 Cancer
|
||||||||||
|
BR2018 Cancer
|
||||||||||
| IMD | ||||||||||
|
BR1007 CKD
|
||||||||||
|
BR3003 Diabetes
|
||||||||||
|
BR3005 Diabetes
|
||||||||||
|
BR3006 Diabetes
|
||||||||||
|
BR1015 Hypertension
|
||||||||||
|
BR1017 Hypertension/Dyslipidemia
|
||||||||||
|
BR1018 Hypertension/Dyslipidemia
|
||||||||||
|
BR1019 Hypertension/Diabetes
|
||||||||||
|
BR6002 Gastrointestinal
|
||||||||||
| Anti-cancer Generic | ||||||||||
|
BR9008 Cancer
|
||||||||||
|
BR9011 Cancer
|
||||||||||
|
BR9012 Cancer
|
||||||||||
|
BR2009 Cancer
|
||||||||||
|
BR2013 Cancer
|
||||||||||
|
BR2015 Cancer
|
||||||||||
|
BR2016 Cancer
|
||||||||||
|
BR2019 Cancer
|
||||||||||
|
BR2021 Cancer
|
||||||||||
|
BR2022 Cancer
|
